Furthermore, data of Surowiak et al (2006) indicated that MRP2 could confer resistance to CDDP in ovarian carcinoma only when expressed at the nuclear membrane, and this was supported by in vitro data (Materna et al, 2006). This evidence concerns the gene ABCC2 and ovarian carcinoma.